EUVIMEDEUVIMED entdecken
Crossref

Dental Management of Persons With Haemophilia Receiving Emicizumab Prophylaxis

Branislav V Bajkin iD, Miryam E Parreira iD, Zikra A Alkhayal

Haemophilia · 16.04.2026

DOI: 10.1111/hae.70237 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, online erschienen am 16.04.2026. Verfasst von Branislav V Bajkin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Novi Sad, Dentistry Clinic of Vojvodina, Novi Sad, Serbia. Die Arbeit nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The use of emicizumab prophylaxis among persons with haemophilia A (PwHA), both with and without inhibitors, has been increasing significantly in recent years. Nevertheless, clear recommendations remain lacking regarding the necessity and extent of perioperative adjunctive systemic haemostatic therapy for surgical procedures. Given the high frequency of dental interventions, minor oral surgical procedures, are of particular clinical relevance for these persons. This paper provides a review of the literature along with a retrospective analysis of a case series involving 10 PwHA who underwent invasive dental procedures across three centres. In cases involving permanent tooth extraction a single preoperative dose of rFVIII (for PwHA without inhibitors) or rFVIIa (for those with inhibitors) were used. The analysis indicated that extraction of primary teeth in children receiving emicizumab prophylaxis can be successfully performed without the concomitant use of systemic haemostatic agents. Only one postoperative bleeding event was observed, following a periodontal procedure, suggesting that type of procedure may pose a greater challenge in achieving adequate hemostasis due to larger bleeding area and limited possibility for the use of local haemostatic measures. A review of the literature showed that for minor oral surgical procedures, such as tooth extraction, either preoperative administration of haemostatic factor infusions or performing the procedure without factor use may be recommended. However, evidence‐based data and recommendations regarding the safest management strategies remain insufficient. A multidisciplinary and individualized approach, incorporating assessment of the procedural bleeding risk, the patient's bleeding history, and strict use of local haemostatic measures remains essential.

Schlagwörter

Stichwörter der Autor:innen

emicizumabhaemophilia Alocal hemostasisoral surgerypostoperative hemorrhagetooth extraction

Autor:innen und Institutionen

  • Faculty of Medicine, University of Novi Sad, Dentistry Clinic of Vojvodina, Novi Sad, Serbia.
  • Foundation of Hemophilia of Buenos Aires, Faculty of Dentistry - University of Buenos Aires, Buenos Aires, Argentina.
  • King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

ORCID-Profile: Branislav V Bajkin, Miryam E Parreira

Zitieren

APA

Bajkin, B. V., Parreira, M. E., & Alkhayal, Z. A. (2026). Dental Management of Persons With Haemophilia Receiving Emicizumab Prophylaxis. Haemophilia. https://doi.org/10.1111/hae.70237

Vancouver

Bajkin BV, Parreira ME, Alkhayal ZA. Dental Management of Persons With Haemophilia Receiving Emicizumab Prophylaxis. Haemophilia. 2026. doi:10.1111/hae.70237

BibTeX
@article{Bajkin2026,
  author = {Bajkin, Branislav V and Parreira, Miryam E and Alkhayal, Zikra A},
  title = {Dental Management of Persons With Haemophilia Receiving Emicizumab Prophylaxis},
  journal = {Haemophilia},
  year = {2026},
  doi = {10.1111/hae.70237}
}
Kostenlos starten →